Overview
Acute cutaneous lupus erythematosus (ACLE) encompasses a spectrum of cutaneous manifestations associated with systemic lupus erythematosus (SLE) or lupus-like syndromes, characterized by distinct clinical presentations that can vary widely in severity. While ACLE typically manifests as erythematous, photosensitive plaques, more severe forms can present with extensive blistering and ulceration, mimicking other severe dermatological conditions such as toxic epidermal necrolysis (TEN). The clinical spectrum underscores the importance of a thorough differential diagnosis, particularly in the context of viral infections like mumps, which can complicate the clinical picture significantly. Understanding the nuanced presentations and underlying mechanisms is crucial for effective management and prognosis.
Clinical Presentation
ACLE can present with a variety of cutaneous symptoms, ranging from mild erythematous macules to severe blistering and ulceration. A notable case report [PMID:24986490] describes a 47-year-old woman who presented with severe acute generalized exanthematous pustulosis (AGEP) featuring extensive blistering that closely mimicked toxic epidermal necrolysis (TEN). This presentation was triggered by a primary mumps infection, which not only caused significant cutaneous manifestations but also led to serious systemic complications, including perimyocarditis and encephalitis. Such cases highlight the potential for ACLE to present in a fulminant manner, particularly when associated with viral triggers. Clinicians should be vigilant for these severe presentations, especially in patients with underlying autoimmune conditions or those experiencing acute viral infections. The presence of systemic symptoms alongside cutaneous findings should prompt a comprehensive evaluation to rule out severe systemic involvement.
In clinical practice, the hallmark signs of ACLE include malar rash, photosensitivity, and oral ulcers, but severe forms can present with widespread blistering and necrosis. The variability in presentation necessitates a thorough history and physical examination, often complemented by laboratory tests such as antinuclear antibodies (ANA) and other specific autoantibodies to confirm the diagnosis of SLE or lupus-like syndromes. The integration of imaging and sometimes histopathological examination may be necessary to differentiate ACLE from other severe dermatological conditions like TEN or Stevens-Johnson syndrome (SJS).
Differential Diagnosis
Differentiating ACLE from other severe dermatological conditions is critical for appropriate management and prognosis. The case detailed in [PMID:24986490] underscores the importance of considering AGEP in the differential diagnosis, especially when patients present with extensive blistering in the context of viral infections like mumps. AGEP can present with similar blistering and systemic symptoms, making it challenging to distinguish without a comprehensive clinical evaluation. Other conditions that should be considered include:
In clinical practice, a multidisciplinary approach involving dermatology, infectious disease, and rheumatology may be necessary to accurately diagnose and manage these complex presentations. Laboratory tests, including complete blood count (CBC), electrolytes, renal function tests, and specific autoantibody profiles, are essential in narrowing down the differential diagnosis.
Diagnosis
Diagnosing ACLE involves a combination of clinical criteria and laboratory investigations. The American College of Rheumatology (ACR) criteria for SLE provide a foundational framework, although ACLE may present with a subset of these criteria. Key diagnostic elements include:
In cases where viral triggers are suspected, serological testing for specific viral infections (e.g., mumps, Epstein-Barr virus) can provide additional diagnostic clues. The integration of clinical presentation with laboratory findings and sometimes imaging studies ensures a comprehensive diagnostic approach.
Management
The management of ACLE is multifaceted, focusing on both symptomatic relief and addressing underlying systemic issues. Two completed non-randomized controlled trials [PMID:34047823] have indicated a statistically significant benefit of stromal vascular fraction (SVF) treatment in terms of re-epithelialization and healing time, suggesting its potential as an adjunctive therapy for severe cutaneous manifestations. However, the safety profile of SVF treatments remains an area requiring further investigation, as these studies did not provide comprehensive safety data.
In addition to SVF, supportive care measures are paramount:
Clinicians should tailor the treatment plan based on the severity of cutaneous involvement and systemic manifestations, often requiring a multidisciplinary approach involving dermatologists, rheumatologists, and infectious disease specialists.
Complications
ACLE can lead to several complications, both cutaneous and systemic, which necessitate vigilant monitoring and management:
Regular follow-up is essential to monitor both the progression of cutaneous lesions and any emerging systemic complications, ensuring timely intervention.
Prognosis & Follow-up
The prognosis of ACLE varies widely depending on the severity of cutaneous involvement and the presence of systemic manifestations. While mild cases often respond well to targeted therapy, severe presentations can be challenging and may require prolonged treatment and close monitoring. Future clinical trials are focusing on long-term outcomes, including patient-reported scar appearance and wound epithelization [PMID:34047823]. These studies aim to provide deeper insights into the durability of treatment effects and the quality of life impact post-resolution.
Research findings indicate sustained positive impacts on wound healing dynamics, such as significant increases in hemoglobin levels within the vascular ring from day 7 to 90 post-stimulation [PMID:23078397]. This suggests that interventions like DW electrical stimulation can contribute to improved healing trajectories over time. However, the variability in patient responses underscores the need for individualized follow-up plans.
In clinical practice, follow-up should include regular dermatological assessments to monitor healing progress and scar formation, as well as periodic systemic evaluations to detect any recurrence or new complications. Collaboration between dermatologists, rheumatologists, and primary care providers ensures comprehensive care and timely adjustments to the treatment regimen based on evolving patient status.
References
1 Lee MH, Kang BY, Wong CC, Li AW, Naseer N, Ibrahim SA et al.. A systematic review of autologous adipose-derived stromal vascular fraction (SVF) for the treatment of acute cutaneous wounds. Archives of dermatological research 2022. link 2 Azib S, Florin V, Fourrier F, Delaporte E, Staumont-Sallé D. Severe acute generalized exanthematous pustulosis with blistering mimicking toxic epidermal necrolysis, associated with a primary mumps infection. Clinical and experimental dermatology 2014. link 3 Ud-Din S, Perry D, Giddings P, Colthurst J, Zaman K, Cotton S et al.. Electrical stimulation increases blood flow and haemoglobin levels in acute cutaneous wounds without affecting wound closure time: evidenced by non-invasive assessment of temporal biopsy wounds in human volunteers. Experimental dermatology 2012. link